Show simple item record

AuthorMassoud, Gaelle P.
AuthorEid, Ali E.
AuthorBooz, George W.
AuthorRached, Layale
AuthorYabluchanskiy, Andriy
AuthorZouein, Fouad A.
Available date2024-11-04T11:07:32Z
Publication Date2023
Publication NameAnti-Aging Pharmacology
Identifierhttp://dx.doi.org/10.1016/B978-0-12-823679-6.00009-6
CitationMassoud, G. P., Eid, A. E., Booz, G. W., Rached, L., Yabluchanskiy, A., & Zouein, F. A. (2023). Senolytics in diseases: killing to survive. In Anti-Aging Pharmacology (pp. 245-267). Academic Press.
ISBN978-012823679-6
ISBN978-012823680-2
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150107473&origin=inward
URIhttp://hdl.handle.net/10576/60857
AbstractSince the discovery of cellular senescence in 1961, numerous studies have investigated the role of senescent cells in the pathogenesis of many chronic diseases. Cellular senescence, defined by irreversible cell cycle arrest, is induced by multiple stressors that activate the DNA damage response, leading to the senescent state. It is characterized by a senescence-associated secretory phenotype that acts on healthy neighboring cells by creating a proinflammatory milieu, affecting their function and potentially inducing their senescence. This book chapter elaborates on the role of senescent cells in the onset and progression of cancer, cardiovascular, metabolic, hepatic, renal, lung, neurodegenerative, bone, and skin diseases. The potential benefits of senolytic drugs that specifically target and eliminate senescent cells in treating these diseases are reviewed to shed light on new therapeutic strategies for managing chronic diseases.
Languageen
PublisherElsevier
SubjectAging
Senescence
Senescence-associated secretory phenotype
Senolytics
TitleSenolytics in diseases: killing to survive
TypeBook chapter
Pagination245-267
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record